Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Dilutive issuance
confidence 95%
filed 2026-09-25
EX-99.1
First Mining completed a public offering of 68,459,500 common shares at C$0.84 per share on September 24, 2026, raising C$57.5 million in gross proceeds. The underwriters' over-allotment option was exercised in full, increasing the dilution. This is a material equity issuance that would significantly affect shareholder ownership percentages and is disclosed as a formal Material Change Report under Canadian securities law (Form 51-102F3).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-09-25
Item 8.01
Nauticus announced a non-binding letter of intent for a private placement equity investment of up to $50 million. The disclosure explicitly states the investment "could result in dilution to existing stockholders and/or a change of control of the Company." While the LOI is non-binding and subject to due diligence and definitive agreements, the contemplated private equity placement is a material capital-raising event that would dilute existing shareholders. This fits the dilutive_issuance category, though the non-binding nature and contingencies create some uncertainty about whether this will ultimately close.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-25
Item 3.02
Golub Capital Private Income Fund S issued 81,237 common shares of beneficial interest for $1,970,000 in consideration pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-25
Item 3.02
The Fund sold 96,269 unregistered common shares for $2.34 million as of September 1, 2026, pursuant to subscription agreements and exempt from Securities Act registration under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
Lord Abbett Private Credit Fund issued approximately 1.74 million common shares for $43.2 million ($24.84 per share) to accredited investors pursuant to subscription agreements, relying on Section 4(a)(2) and Regulation D exemptions from Securities Act registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
The Company issued approximately 565,990 common shares for $13.9 million to accredited investors pursuant to subscription agreements, relying on Section 4(a)(2) and Regulation D exemptions from Securities Act registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-09-24
Item 1.01
DevvStream entered into a First Amendment to a Securities Purchase Agreement on September 21, 2026, restructuring an equity investment. The Amendment involves the issuance of common shares at discounted prices ($0.28683 and $0.1785 per share, representing 90% and 85% of VWAP respectively) in exchange for cash funding. The company is issuing 1,681,756 shares total (561,308 retained plus 1,120,448 new shares), which is dilutive to existing shareholders. While technically a private placement amendment rather than a new unregistered issuance, the substance is a dilutive equity raise at below-market pricing, characteristic of a PIPE-like transaction at a small-cap issuer under financial stress (evidenced by the restructuring of the original $5M funding commitment).
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-24
EX-99.1
IM Cannabis announced pricing of a registered direct offering of 655,000 common shares at US$2.00 per share for gross proceeds of approximately US$1.31 million. This is a registered equity issuance to accredited investors pursuant to an effective Form F-3 shelf registration statement. The disclosure explicitly states the offering is being made "only by means of a prospectus which is part of the effective registration statement," confirming this is a registered offering of equity securities that will dilute existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
EQT Infrastructure sold approximately $104.4 million in unregistered Investor Shares across multiple share classes to third-party investors as of September 1, 2026, relying on Section 4(a)(2) and Regulations D and S exemptions. This is a classic dilutive private placement of equity securities. The filing explicitly discloses this under Item 3.02 (Unregistered Sales of Equity Securities), and the cumulative offering since inception ($1.008 billion) demonstrates material capital-raising activity that would affect investor assessment of ownership dilution and the company's financing strategy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
EQT Private Equity Company LLC disclosed an unregistered sale of approximately $28.1 million in equity shares (990,093 shares across multiple classes) to third-party investors as of September 1, 2026, relying on Section 4(a)(2) and Regulations D and S exemptions. This is a classic dilutive issuance of unregistered equity securities. The disclosure notes cumulative sales of approximately $861.1 million since inception on July 1, 2025, indicating a material ongoing capital-raising activity that would affect investor assessment of ownership dilution and the company's capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
North Haven Private Income Fund LLC completed an unregistered sale of approximately 432,819 Class S units for $7.73 million to accredited investors pursuant to subscription agreements, relying on Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
North Haven Private Income Fund A LLC completed an unregistered sale of approximately 135,464 Class I units for $2.6 million to accredited investors, relying on Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
LGAM Private Credit LLC sold approximately 55,206 Common Units for $1.1 million (~$19.46 per unit) pursuant to subscription agreements, relying on Regulation S and other exemptions from Securities Act registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-09-24
Item 3.02
Jaguar Health completed a debt-for-equity exchange on September 23, 2026, issuing 729,989 shares of common stock (including 182,091 shares under Item 1.01 and 547,898 shares under Item 1.02) to reduce and fully cancel approximately $6.73M in secured promissory note obligations. The transaction materially restructures the company's capital structure through equity dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 1.01
New ERA Energy & Digital entered into an At-The-Market (ATM) Issuance Sales Agreement on September 24, 2026, authorizing the sale of up to $100 million in common stock through multiple agents at commissions up to 3.5%. Proceeds are intended for general corporate purposes including debt refinancing.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-24
AIFU completed issuance of 10,000,000 Class B ordinary shares to Expansion Group Ltd. at US$0.002 per share on September 24, 2026, raising US$20,000 in gross proceeds. Post-issuance, Expansion holds approximately 63.37% of total shares and 99.43% of voting power, representing a material dilutive equity issuance that substantially shifts control and ownership structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-09-24
Item 3.02
Big Digital Energy exchanged $2.57 million in debt (principal plus accrued interest) for 442,899 shares of common stock in an unregistered equity transaction with a related party. The debt-for-equity conversion is material to the company's capital structure and represents a dilutive issuance of equity securities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
Live Oak Acquisition Corp. VI completed a private placement of 4,600,000 warrants to the Sponsor at $1.00 per warrant ($4.6 million aggregate) simultaneously with the IPO closing, exercisable for Class A ordinary shares at $11.50 per share, issued pursuant to Section 4(a)(2) exemption from registration.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-09-24
EX-99.1
This exhibit is a Securities Purchase Agreement for an unregistered private placement of 40,000,000 Class A Ordinary Shares at $0.3 per share for an aggregate purchase price of $12,000,000. The agreement explicitly relies on Section 4(a)(2) of the Securities Act and Regulation S exemptions from registration, and the purchasers are identified as "non-US persons." This is a classic dilutive equity issuance to foreign investors outside the registered public offering process, material to existing shareholders due to the substantial share count increase (40 million shares against a current outstanding base of ~39.9 million shares).
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-24
The 6-K discloses entry into a Securities Purchase Agreement on September 22, 2026, pursuant to which Pop Culture Group agreed to sell and issue 665,000 Class A ordinary shares at US$3.00 per share in a registered direct offering. The offering closed on September 24, 2026. This is a registered direct offering of equity securities that would dilute existing shareholders and is material to investor assessment of capital structure and ownership.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-09-24
The 6-K discloses termination of an "at the market" (ATM) offering agreement under which the Company sold approximately 981,261 Class A Ordinary Shares (post-consolidation) and received ~$21.15 million in net proceeds. While the ATM program itself has ended, the disclosure documents the completion of a dilutive equity issuance that raised material capital and resulted in significant share dilution to existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-24
EX-99.1
This news release announces the closing of a $57.5 million bought-deal public offering in which First Mining issued 68,459,500 common shares at $0.84 per share. The offering was completed through a syndicate of underwriters and included full exercise of the over-allotment option. This is a material equity issuance that dilutes existing shareholders and represents a significant capital raise for the company's gold development projects.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 1.01
Patriot National Bancorp entered into a securities purchase agreement to issue 4,782,608 shares of voting common stock and 956,522 warrants in a registered direct offering to accredited investors, raising approximately $5.5 million in gross proceeds. This is a dilutive equity issuance to raise capital, characteristic of a PIPE or registered direct offering, which materially affects existing shareholders through dilution and is a key financing event for a small-cap bank holding company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-24
Newton Golf Company issued 232,202 shares of common stock in exchange for warrant repurchases on September 21-22, 2026. Item 3.02 explicitly discloses this as an unregistered sale of equity securities exempt under Section 3(a)(9). The filing also grants warrant holders a 12-month pro rata purchase option on future equity issuances up to 10% of any offering, which is a material dilutive commitment. This is a classic dilutive issuance event involving unregistered equity sales and future dilution rights.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 1.01
Brightline Interactive entered into securities purchase agreements on September 23, 2026, to sell 1,785,711 units (each comprising one share of common stock and one warrant) for $0.70 per unit, generating $1.25 million in gross proceeds. This is a classic private investment in public equity (PIPE) transaction—an unregistered sale of equity securities to raise capital. The filing explicitly discloses reliance on Section 4(a)(2) exemption from Securities Act registration (Item 3.02), and the company commits to file a registration statement within 30 days. The dilutive nature is evident: new shares and warrants are being issued at a price ($0.70) described as "above the Company's closing share price on September 23, 2026," yet the issuance of 1.78+ million units will dilute existing shareholders. This is a material capital-raising event typical of small- to mid-cap issuers.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-24
The Company completed a private placement on September 3, 2026, issuing 15,000,000 Class A ordinary shares at $1.266 per share plus warrants to purchase 15,000,000 additional shares at $0.50 per share, for an aggregate of $18.99 million. This is a classic dilutive equity issuance to non-U.S. investors that materially increases share count and is a strong signal of capital-raising activity typical of small- and mid-cap issuers.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
HCW Biologics entered into a Securities Purchase Agreement on September 23, 2026, to issue 903,614 pre-funded warrant units at $1.6599 per unit for approximately $1.5 million in gross proceeds. The filing explicitly discloses this as an unregistered private placement under Section 4(a)(2) and Regulation D (Item 3.02), with the investor receiving pre-funded warrants exercisable immediately at $0.0001 per share and common warrants (subject to stockholder approval) exercisable at $1.66 per share. This is a classic dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital for working capital and clinical development activities.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 45%
filed 2026-09-24
EX-99.1
FBS Global announced a 1-for-10 reverse stock split (share consolidation) approved by shareholders on September 13, 2026, intended to increase per-share trading price to meet Nasdaq's US$1.00 minimum bid price requirement for continued listing. While a reverse split is technically a capital restructuring rather than a dilutive issuance of new equity, it is material to investors as it signals delisting risk and represents a significant corporate action affecting share structure and trading. The disclosure emphasizes the split is conditional on Nasdaq clearance and directly addresses compliance with listing standards.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-24
The filing discloses an unregistered sale of 234,251,400 common shares (20% of aggregate note principal) to four noteholders in exchange for maturity extensions of secured promissory notes. The transaction is explicitly disclosed under Item 3.02 (Unregistered Sales of Equity Securities) and relies on Section 4(a)(2) and Regulation D exemptions. This represents a highly dilutive equity issuance to settle debt obligations, characteristic of financial distress at a micro-cap company (stock price $0.0009).
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-09-24
SafeSpace Global entered into an equity line of credit (ELOC) providing up to $10 million in equity financing capacity and a convertible note for up to $1 million, both with Crom Structured Opportunities Fund I, LP. The ELOC allows the Company to issue newly issued common shares on a pro rata basis over 36 months, and the convertible note is convertible into common stock. These are classic dilutive equity issuances—unregistered sales of equity securities under Section 4(a)(2) of the Securities Act—that would materially dilute existing shareholders and represent a significant capital raise for the company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Glucotrack entered into a securities purchase agreement on September 24, 2026, to issue 169,388 shares of common stock at $2.04 per share and pre-funded warrants to purchase 1,350,220 additional shares at $2.039 per warrant, generating approximately $3.1 million in gross proceeds. This is a registered direct offering of equity securities that will dilute existing shareholders, with the company intending to use proceeds to pay off debt and for working capital. The filing explicitly discloses lock-up agreements and lock-up restrictions on variable rate transactions, which are hallmarks of dilutive equity issuances.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 1.01
Forward Industries completed a registered direct offering of 3,125,000 shares of common stock at $8.00 per share, raising approximately $25 million in gross proceeds under its Form S-3ASR shelf registration statement. The company intends to use proceeds to acquire additional Solana cryptocurrency, materially diluting existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
The filing discloses multiple unregistered sales of equity securities totaling approximately $14.3 million across Class C, Class E, and Class I common shares issued to the Adviser, Brookfield affiliates, and feeder vehicles. These issuances are exempt from registration under Section 4(a)(2) of the Securities Act and Regulation S, representing dilutive equity issuances that would materially affect shareholder ownership and voting power. The scale and frequency of these unregistered issuances to related parties and feeder vehicles constitute material capital events for the REIT.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
Endovia completed an unregistered sale of 3,629,250 shares of common stock to an investor under an ELOC Agreement for approximately $809,000 in gross proceeds during August-September 2026, relying on Section 4(a)(2) and Rule 506(b) exemptions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
The filing discloses an unregistered sale of 191,695 common shares for $5,016,662 pursuant to Section 4(a)(2) and Regulation D/S under the Securities Act. This is a classic dilutive equity issuance exempt from registration, which is material to investors as it increases share count and dilutes existing shareholders' ownership interests.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-24
Item 3.02
TPG Private Equity Opportunities, L.P. sold unregistered limited partnership units totaling $102.8 million on September 1, 2026, as part of a continuous private offering exempt under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-23
Item 3.02
FMC completed an unregistered sale of 30,319,166 shares of common stock to Tessenderlo Group for approximately $403.2 million at $13.30 per share on September 23, 2026, resulting in Tessenderlo owning approximately 20% of FMC's outstanding shares. The transaction includes governance provisions granting Tessenderlo board nomination rights and other shareholder protections. This material dilutive equity issuance significantly affects ownership structure and represents a substantial capital raise.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-09-23
The 6-K discloses a redemption and cancellation of 66,668 Class A ordinary shares (100% of shares issued in the August 2025 private placement for $6 million in Dogecoin) that occurred on September 22, 2026. While this is technically a share cancellation rather than a new issuance, it represents the resolution of a dilutive private placement transaction (the original August 2025 DOGE-funded securities purchase) that was material to the registrant's capital structure. The disclosure documents the full unwinding of that dilutive event through investor redemption rights.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 94%
filed 2026-09-23
EX-99.1
Hafnia Limited announced a contemplated offering of approximately USD 300 million in ordinary shares through an accelerated bookbuilding process, structured as a private placement under the Company's effective Form F-3 shelf registration statement. The offering will be supported by a share lending agreement with BW Group Limited to facilitate settlement, and proceeds will be used to strengthen the balance sheet and fund strategic opportunities.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-23
Item 8.01
Beyond Meat entered into exchange agreements to convert approximately $15.0 million principal of 0% Convertible Senior Notes due 2027 into common stock, with 1,097,444 shares issued initially and up to 848,265 additional shares potentially issued in final settlement, using the Section 4(a)(2) private placement exemption.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-23
Item 3.02
The filing discloses an unregistered sale of equity securities (common stock) pursuant to Item 3.02, with an aggregate offering price of $8.7 million. The shares are being issued under subscription agreements to existing investors via capital calls, exempt from Securities Act registration under Section 4(a)(2) and Regulation D. This is a classic dilutive issuance of unregistered equity to raise capital.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-23
EX-99.1
This press release announces a $50 million PIPE (private investment in public equity) financing in which Maase Inc. will issue 3,878,856 Class A ordinary shares at $12.89 per share to a financial investment institution. PIPE financings are unregistered equity issuances that are dilutive to existing shareholders and represent a material capital-raising event. The disclosure explicitly identifies this as a securities purchase agreement for private equity issuance, which is the hallmark of a dilutive_issuance event.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-09-23
The 6-K discloses the closing of a private placement to "non-U.S. Persons" pursuant to a securities purchase agreement dated September 15, 2026, which closed on September 22, 2026. This is an unregistered sale of equity securities to foreign investors, a classic dilutive issuance. The filing references a prior 6-K disclosure on September 21, 2026 regarding entry into the SPA, and this filing confirms consummation of the transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-23
Item 3.02
The Company issued 193,125 Class A ordinary shares to underwriters ($1.93M) and 1,750,000 warrants to the Sponsor ($3.5M) pursuant to Section 4(a)(2) private placements, concurrent with the IPO.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-23
Item 3.02
The filing discloses an unregistered sale of 31,037,830 common shares at $1.25 per share (a premium to market under Nasdaq rules) for gross proceeds of $38.8 million to two Samoa-based entities. The transaction closed on September 22, 2026, and was exempted under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive private placement that materially affects shareholder equity and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-23
Item 1.01
Greenland Mines entered into a securities purchase agreement to sell 1,765,420 shares of common stock and pre-funded warrants exercisable for 1,434,580 additional shares in a registered direct offering, raising approximately $38.4 million in net proceeds. This is a material dilutive equity issuance to institutional investors at $12.00 per share, representing a substantial capital raise that would significantly dilute existing shareholders and materially affect the registrant's capitalization.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 72%
filed 2026-09-23
Item 8.01
Visa deposited $405 million into a litigation escrow account under its retrospective responsibility plan, triggering downward adjustments to conversion rates for class B-1, B-2, and B-3 common stock held by U.S. financial institutions. These conversion rate reductions resulted in dilution equivalent to a share repurchase, reducing as-converted share counts by approximately 1.1 million shares across the three classes. While this is a structured capital event tied to litigation funding rather than a traditional equity issuance, the mechanism—conversion rate adjustments that dilute existing shareholders—aligns with the dilutive effects disclosed under Item 3.02 frameworks and materially affects share counts and EPS.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-09-23
Item 8.01
Moleculin completed two dilutive equity issuances: (1) an ATM offering of 888,400 shares for $0.48 million in September 2026, and (2) a public offering of Series I Warrants to purchase 37,130,001 shares on August 3, 2026, with anti-dilution provisions that reduced the warrant exercise price from $0.75 to $0.51 per share following the ATM issuance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-23
Eva Live Inc. entered into an Equity Purchase Agreement with Hudson Global Ventures, LLC granting the investor the right to purchase up to $10,000,000 of common stock at $2.00 per share, plus issued a warrant to purchase 275,000 shares at $0.01 per share. The warrant and shares were offered in a private placement exempt from registration under Section 4(a)(2) and Rule 506(b). This is a classic dilutive equity issuance to raise capital, with the warrant exercise price of $0.01 being substantially below market, creating significant dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-23
Item 3.02
Decoy Therapeutics entered into a warrant inducement agreement with an institutional investor, issuing 2,368,868 unregistered new warrants (representing 200% of exercised existing warrants) in a private placement under Section 4(a)(2) of the Securities Act. The transaction generated $3.85 million in gross proceeds from the exercise of 1,184,434 Series B Milestone Warrants and included a reduction in exercise prices of existing warrants from $5.91 to $3.25 per share, resulting in substantial dilution to existing shareholders.
View raw filing on EDGAR →